Catheter Precision (NYSEAMERICAN:VTAK) Posts Quarterly Earnings Results, Beats Estimates By $18.08 EPS

Catheter Precision (NYSEAMERICAN:VTAK) issued its quarterly earnings data on Friday. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($19.00) by $18.08, FiscalAI reports. Catheter Precision had a negative return on equity of 76.51% and a negative net margin of 1,297.56%.The company had revenue of $1.02 million during the quarter, compared to analysts’ expectations of $2.00 million.

Catheter Precision Stock Down 3.4%

NYSEAMERICAN VTAK traded down $0.01 during mid-day trading on Friday, hitting $0.28. The company’s stock had a trading volume of 679,930 shares, compared to its average volume of 7,092,899. The company has a current ratio of 0.06, a quick ratio of 0.06 and a debt-to-equity ratio of 0.35. The company’s 50 day simple moving average is $0.67 and its 200 day simple moving average is $1.05. Catheter Precision has a twelve month low of $0.23 and a twelve month high of $4.31. The firm has a market capitalization of $1.01 million, a price-to-earnings ratio of -0.02 and a beta of -1.00.

Institutional Trading of Catheter Precision

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC bought a new position in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision as of its most recent SEC filing. 20.34% of the stock is owned by institutional investors and hedge funds.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.